Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ionis Pharmaceuticals has the Profitability Rank of 3. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Ionis Pharmaceuticals Profitability Rank Related Terms
MEX:IONS vs KYMR, PRAX, HALO: Profitability Rank Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Profitability Rank vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Ionis Pharmaceuticals has the Profitability Rank of 3. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (MEX:IONS) has a Profitability Rank of 3 as of Jun. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Ionis Pharmaceuticals and its competitors. This is near median its historical median of 3.00. Over the past decade, Ionis Pharmaceuticals' Profitability Rank has ranged from 1.00 to 4.00.
Is Ionis Pharmaceuticals' Profitability Rank too high?
Ionis Pharmaceuticals' current Profitability Rank of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Profitability Rank compare to KYMR and PRAX?
Ionis Pharmaceuticals' Profitability Rank of 3 can be compared against companies in the Biotechnology industry. Historically, Ionis Pharmaceuticals' own Profitability Rank has ranged from 1.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Biotechnology company?
A good Profitability Rank depends on the Biotechnology industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Profitability Rank is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Profitability Rank of 3. The stock's GF Value™ is MXN1,061.81, compared to a current price of MXN1,150.00 — trading 8.3% above its estimated fair value. The current Profitability Rank is 3, which is near median its 10-year median of 3.00. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Profitability Rank is 3 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,150.00 is trading 8.3% above its estimated GF Value™ of MXN1,061.81.
Key valuation signals for MEX:IONS:
Profitability Rank: 3 (near median its 10-year median of 3.00)
GF Value™: MXN1,061.81 vs. price of MXN1,150.00 (8.3% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score
Get the complete analysis for MEX:IONS
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
